Intellia Therapeutics Stock Options
| NTLA Stock | USD 15.62 0.41 2.70% |
Intellia Therapeutics' latest option contracts expiring on 2024-12-20 are carrying combined implied volatility of 1.11 with a put-to-call open interest ratio of 0.56 over 17 outstanding agreements suggesting investors are buying more calls than puts on contracts expiring on 2024-12-20. The total put volume is at 54.0, with calls trading at the volume of 54.0. This yields a 0.11 put-to-call volume ratio.
Open Interest Against 2024-12-20 Option Contracts
2024-12-20
The chart above shows Intellia Therapeutics' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Intellia Therapeutics' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Intellia Therapeutics' option, there is no secondary market available for investors to trade.
Intellia Therapeutics Maximum Pain Price across 2024-12-20 Option Contracts
Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of particular securities such as Intellia Therapeutics close to expiration to expire worthless. So, Max pain occurs when market makers reach a net positive position across all options at a strike price where option holders stand to lose the most money. By contrast, Intellia Therapeutics' option sellers may reap the most after selling more options than buying, causing them to expire worthless.
Intellia Therapeutics' option chain provides insight into all available option contracts written on Intellia Therapeutics' stock. Investors can see outstanding put and call contracts with pricing information and greeks for a given expiration period. In addition, each of Intellia Therapeutics' stock options below provides a detailed picture of the payoff. Comparing vital and dynamic information of various option contracts across diverse expiration periods will help you make an educated decision on your market timing strategies around investing in a given Intellia option contract.
In The Money vs. Out of Money Option Contracts on Intellia Therapeutics
Analyzing Intellia Therapeutics' in-the-money options over time can help investors to take a profitable long position in Intellia Therapeutics regardless of its overall volatility. This is especially true when Intellia Therapeutics' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Intellia Therapeutics' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Intellia Therapeutics' stock while costing only a fraction of its price.
Intellia Therapeutics' stock options are financial instruments that give investors the right to buy or sell shares of Intellia Therapeutics common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Intellia stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Intellia Therapeutics' stock price goes up or down, the stock options follow.
At present, Intellia Therapeutics' Other Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Stock Based Compensation is expected to grow to about 140.8 M, whereas Total Stockholder Equity is forecasted to decline to about 548.5 M. Intellia Therapeutics In The Money Call Balance
When Intellia Therapeutics' strike price is surpassing the current stock price, the option contract against Intellia Therapeutics stock is said to be in the money. When it comes to buying Intellia Therapeutics' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Intellia Therapeutics are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Intellia Current Options Market Mood
Intellia Therapeutics' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Intellia Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most Intellia Therapeutics' options investors are not very successful. Intellia Therapeutics' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Intellia contract
Base on the Rule 16, the options market is currently suggesting that Intellia Therapeutics will have an average daily up or down price movement of about 0.0694% per day over the life of the 2024-12-20 option contract. With Intellia Therapeutics trading at USD 15.62, that is roughly USD 0.0108. If you think that the market is fully incorporating Intellia Therapeutics' daily price movement you should consider buying Intellia Therapeutics options at the current volatility level of 1.11%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Intellia |
Purchasing Intellia Therapeutics options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Intellia calls. Remember, the seller must deliver Intellia Therapeutics stock to the call owner when a call is exercised.
Intellia Therapeutics Option Chain
When Intellia Therapeutics' strike price is surpassing the current stock price, the option contract against Intellia Therapeutics stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Intellia Therapeutics' option chain is a display of a range of information that helps investors for ways to trade options on Intellia. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Intellia. It also shows strike prices and maturity days for a Intellia Therapeutics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Expiration | Current Spread | Last Price | |||
Call | NTLA Option Call 20-12-2024 10 | 0 | 2024-12-20 | 5.3 - 6.2 | 5.5 | In |
Call | NTLA Option Call 20-12-2024 12 | 0 | 2024-12-20 | 3.2 - 3.5 | 3.25 | In |
Call | NTLA Option Call 20-12-2024 15 | 1890 | 2024-12-20 | 1.45 - 1.5 | 1.5 | In |
Call | NTLA Option Call 20-12-2024 17 | 3254 | 2024-12-20 | 0.35 - 0.6 | 0.49 | Out |
Call | NTLA Option Call 20-12-2024 20 | 0 | 2024-12-20 | 0.15 - 0.3 | 0.2 | |
Call | NTLA Option Call 20-12-2024 22 | 1578 | 2024-12-20 | 0.05 - 0.2 | 0.15 | Out |
Call | NTLA Option Call 20-12-2024 25 | 90 | 2024-12-20 | 0.0 - 0.1 | 0.1 | Out |
Call | NTLA Option Call 20-12-2024 30 | 136 | 2024-12-20 | 0.0 - 0.1 | 0.05 | Out |
Call | NTLA Option Call 20-12-2024 35 | 0 | 2024-12-20 | 0.0 - 0.05 | 0.04 | |
Put | NTLA Option Put 20-12-2024 7 | 1 | 2024-12-20 | 0.0 - 0.2 | 0.15 | Out |
Put | NTLA Option Put 20-12-2024 10 | 280 | 2024-12-20 | 0.0 - 0.1 | 0.05 | Out |
Put | NTLA Option Put 20-12-2024 12 | 1055 | 2024-12-20 | 0.15 - 0.3 | 0.25 | Out |
Put | NTLA Option Put 20-12-2024 15 | 2062 | 2024-12-20 | 0.5 - 0.95 | 0.95 | Out |
Put | NTLA Option Put 20-12-2024 17 | 365 | 2024-12-20 | 2.15 - 2.55 | 4.5 | In |
Put | NTLA Option Put 20-12-2024 20 | 110 | 2024-12-20 | 4.3 - 4.9 | 5.4 | In |
Put | NTLA Option Put 20-12-2024 22 | 0 | 2024-12-20 | 6.4 - 7.3 | 8.2 | In |
Put | NTLA Option Put 20-12-2024 25 | 2 | 2024-12-20 | 7.5 - 12.0 | 10.99 | In |
Intellia Total Stockholder Equity
Total Stockholder Equity |
|
Intellia Therapeutics Corporate Management
| JD Esq | General VP | Profile | |
| Jennifer Doudna | Founder Board | Profile | |
| Derek Hicks | Executive Officer | Profile | |
| Andrew May | Founder Board | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. If investors know Intellia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intellia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.45) | Revenue Per Share 0.449 | Quarterly Revenue Growth (0.24) | Return On Assets (0.28) | Return On Equity (0.52) |
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intellia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intellia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intellia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.